To investigate the clinical efficacy and safety of high intensity focused ultrasound (HIFU) combined with ultrasound-guided suction curettage in patients with type I/II/III cesarean scar pregnancy ...
Objective. In the current study, the role of abnormal methylation of Wnt5a gene promoter regions in human epithelial ovarian cancer was investigated. Methods. Wnt5a expressions were examined by immunohistochemistry in epithelial ovarian tissues (30 normal and 79 human EOC tissues). SKOV3 cells were treated with different concentrations of 5-Aza-CdR (0.5, 5, and 50 μmol/L). The methylation status of the Wnt5a promoter was analyzed using a methylation-specific polymerase chain reaction (MSP), and the expression level of Wnt5a mRNA was detected using quantitative real-time polymerase chain reaction (qRT-PCR). Cell proliferation was measured by MTT assay, and apoptosis was analyzed using flow cytometry. Results. (1) Compared with normal tissues, Wnt5a expressions were reduced or lost in EOC (). Wnt5a expression had a close relationship with histological grade, FIGO stage, and lymph node metastasis (, , and , resp.). (2) Wnt5a abnormal methylation status existed in ovarian cancer tissues and was higher than that of normal ovarian tissue (). (3) Before treatment with 5-Aza-CdR, the promoter of the Wnt5a gene was methylated in SKOV3 cells; accordingly, Wnt5a mRNA levels were low to absent in SKOV3 cells. (4) Following 5-Aza-CdR treatment, MSP analysis revealed complete demethylation of the Wnt5a promoter in the SKOV3 cell line, particularly at 5 μmol/L 5-Aza-CdR. Wnt5a expression increased in SKOV3 cells following treatment with a demethylating agent (). (5) The growth rate of the cells was inhibited in a dose-dependent manner by treatment with 5-Aza-CdR. (6) The cell apoptosis rate increased gradually after treatment with 0.5, 5, and 50 μmol/L 5-Aza-CdR. The apoptosis rate exists in a dose-dependent relationship with 5-Aza-CdR concentration (, ). Conclusions. Wnt5a gene region promoter aberrant methylation existed in epithelial ovarian cancer, and abnormal methylation of Wnt5a gene promoter regions may be a new target for the treatment of epithelial ovarian cancer.
Rationale: Intramural ectopic pregnancy (IMP) is a rare ectopic pregnancy with an unclear etiology, and standard treatment guidelines currently remain unclear. The main treatment option is local excision of IMP via laparoscopy or laparotomy. Patient concerns: A 32-year-old woman with adenomyosis presented with amenorrhea for 7 weeks and a serum β-human chorionic gonadotropin (HCG) level of 6882 IU/L. The patient had a history of laparotomy for adenomyosis 5 years previously. Three-dimensional ultrasonography showed a live gestational sac (GS) of 9 × 15 × 18 mm located in the left posterior wall of the uterus and a sinus tract connecting the sac and the endometrial cavity. MRI revealed the GS located in the adenomyosis and a 1.0-cm sinus tract connecting the GS and the endometrial cavity. Diagnoses: IMP with adenomyosis. Interventions: High-intensity focused ultrasound (HIFU) treatment combined with systemic methotrexate (MTX) was performed to treat IMP, which would avoid operation and massive bleeding. Outcomes: Serum β-HCG levels decreased to normal 4 weeks after HIFU treatment and the GS was not found on MRI after 4 months. The sinus tract was significantly shortened after the HIFU treatment. Lessons: HIFU ablation combined with systemic MTX is effective for the treatment of IMP and is favorable for maintaining fertility.
Background Endometriosis (EMs) is a chronic enigmatic gynecological disorder which pathogenesis have not been fully elucidated. Exosomes have been proven to participate in endometriosis. However, the role of exosomes in the pathogenesis of EMs remains poorly defined. Methods Exosomes were isolated from cyst fluid of EMs patients and pelvic fluid of non-EMs patients, and characterized by transmission electron microscopy, nanoparticle tracking analysis and western blot. Exosomal miRNAs were performed by small RNA sequencing. Q-PCR and cell function were performed to identify the relationship between exosomal miRNAs and endometriosis. Dual luciferase reporter assay, cell transfection, Q-PCR, Western blotting and CCK8 assays, Transwell assays and Boyden assays were conducted to explore the regulatory effects of exosomal miRNA on EMs pathogenesis in vitro using primary human endometrial stromal cells (HESCs) derived from endometriotic lesions. Results Compare with non-EMs group, there are 118 miRNAs were up-regulated and 40 miRNAs were down-regulated in CF group, meanwhile 22 miRNAs were up-regulated and 32 miRNAs were down-regulated in PF group. Q-PCR verified that miR-125b-5p, miR-328-3p, miR-125a-5p, miR-30e-3p were significant down-regulated, whereas miR-3141, miR-223-3p, miR-142-5p, miR-1246 were significant up-regulated in EMs patients. ROC analysis indicated that miR-125b-5p (AUC = 0.925, p < 0.001) was highly correlated with EMs pathogenesis. Dual luciferase reporter assay results demonstrated miR-125b-5p directly targeted VEGF gene. MiR-125b-5p suppressed endometrial stromal cells proliferation, migration and invasion by regulating the Phosphatidylinositol 3-Kinase (PI3K) /Protein Kinase B (AKT) signaling pathway. Conclusion Exosomal miR-125b-5p was highly correlated with EMs, and it regulates the PI3K/Akt signaling pathways through VEGF to inhibit endometrial stromal cells proliferation, migration and invasion, acting as an important suppressing miRNA in endometriosis pathogenesis.
30 July 2026 in International Journal of Hyperthermia
Adenomyosis is a benign gynecological disorder characterized by the ectopic infiltration of endometrial glands and stroma into the myometrium, frequently manifesting with dysmenorrhea, menorrhagia,...
Objective To assess the safety and clinical efficacy of high-intensity focused ultrasound (HIFU) combined with gonadotropin-releasing hormone agonists (GnRH-a), hysteroscopic surgery (hysteroscopic resection of adenomyosis and endometrial ablation) and levonorgestrel intrauterine system (LNG-IUS) for the treatment of adenomyosis patients with an unsatisfactory HIFU ablation. Design A retrospective analysis. Setting A specialized hospital in China. Population In all, 25 adenomyosis patients with HIFU ablation, the the non-perfused volume (NPV) ratio<50%, without fertility requirement. Methods All patients underwent HIFU ablation combined with GnRH-a, hysteroscopic surgery and LNG-IUS treatment (HGHL), with a follow-up period of at least 12 months. Main outcome measures The changes in dysmenorrhea and menstrual volume before, and at 3, 6 and 12 months following HGHL treatment. Results All 25 patients enrolled in the study were successfully treated with the HGHL combination with a median follow-up length of 15 months (range, 12–30 months). Mean value of the NPV ratio calculated immediately after the HIFU treatment was (32.8±10.4)%. Mean operation time, median intraoperative blood loss and median length of hospital stay of hysteroscopic surgery were 42.9±12.8 min, 10 (5,15) ml, and 3 (3,3) days, respectively. No significant complications were observed during HGHL treatment. Compared with the symptom scores before the HIFU treatment, the score of dysmenorrhea and menstrual volume decreased significantly at 3, 6 and 12 months after HGHL treatment ( p < 0.05), and no significant difference was observed between 3, 6 and 12 months after HGHL treatment ( p > 0.05). No recurrence was observed during the follow-up. Conclusions HGHL is a novel and effective combination therapy for adenomyosis with unsatisfactory HIFU ablation with the goal of preserving as much of the uterus as possible.